跳到正文
原文
梅斯医学·临床资讯·· 2026-10-20AI 评分35

AHA 2026 FS专场:65项研究聚焦心血管诊疗新进展

AHA 2026丨聚焦14场FS专场!65项研究揭示心血管诊疗新进展

AI 导读

2026美国心脏协会科学会议FS专场将呈现65项心血管领域前沿研究。内容包括BHB/HRS-1893及Aficamten治疗肥厚型心肌病的长期疗效与安全性数据;SRSD216单次给药后脂蛋白(a)降幅达85%的1期结果;以及阿哌沙班预防静脉血栓栓塞复发的HI-PRO试验延长期数据等。

正文

深度解析医学证据,DeepEvidence为你支撑决策

2026年美国心脏协会科学会议(AHA 2026)将于11月6日至9日在美国芝加哥举行。作为大会的重要学术板块,特色科学研究(Featured Science,FS)专场将集中呈现心血管领域多项前沿研究成果,涵盖新型降脂疗法、冠状动脉疾病、心律失常、心力衰竭、血压管理及人工智能应用等多个热点方向。从创新药物的临床探索到疾病管理策略的持续优化,一系列研究将为心血管疾病的预防、诊断与治疗提供新的循证依据。POCKETIN将全程跟踪,第一时间带来改变临床格局的重要发现。

HCMS Late Breaking Oral Abstracts

北京时间:11月7日 03:15

Long-Term Efficacy and Safety of BHB/HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy: Results From the 52-Week Extension Period

BHB/HRS-1893在梗阻性肥厚型心肌病患者中的长期疗效与安全性:52周延长期结果

Effect of Aficamten on Cardiac Structure and Function in Nonobstructive Hypertrophic Cardiomyopathy: The Acacia-HCM CMR Study

Aficamten对非梗阻性肥厚型心肌病患者心脏结构与功能的影响:ACACIA-HCM心脏磁共振研究

Effect of Aficamten on Patient-Reported Health Status in Non-Obstructive Hypertrophic Cardiomyopathy

Aficamten对非梗阻性肥厚型心肌病患者自报健康状况的影响

Outcomes of Mavacamten Treatment in Adolescents With Obstructive Hypertrophic Cardiomyopathy at 56 Weeks: The SCOUT-HCM Trial

Mavacamten治疗青少年梗阻性肥厚型心肌病56周的结局:SCOUT-HCM试验

Stable Ischemic Heart Disease: What Happens in the Long Run

北京时间:11月7日 22:30

Effect of Percutaneous Coronary Intervention on Long-Term Outcomes in Patients With Stable Ischemic Heart Disease: A 25-Year Follow-Up of the COURAGE Trial

经皮冠状动脉介入治疗对稳定性缺血性心脏病患者长期结局的影响:COURAGE试验25年随访

A Randomized Comparison of Personalized Management for Medical and Interventional Therapy Based on Coronary Atherosclerotic Plaque versus Usual Care for Symptomatic Patients With Suspicion of Coronary Artery Disease: Primary Results of the PARAMOUNT Trial

基于冠状动脉粥样硬化斑块的药物与介入治疗个体化管理与常规治疗在有症状疑似冠状动脉疾病患者中的随机比较:PARAMOUNT试验主要结果

Long-Term Survival After Initial Invasive or Conservative Management of Stable Coronary Disease: ISCHEMIA-EXTEND

稳定性冠状动脉疾病初始侵入性或保守治疗后的长期生存:ISCHEMIA-EXTEND研究

Long-Term Survival After Initial Invasive or Conservative Management of Stable Coronary Disease in Advanced Chronic Kidney Disease: ISCHEMIA-CKD EXTEND

晚期慢性肾脏病合并稳定性冠状动脉疾病患者初始侵入性或保守治疗后的长期生存:ISCHEMIA-CKD EXTEND研究

Death, Drugs, Diagnostics in Thrombosis

北京时间:11月7日 22:30

Dynamic Shifts in Cause Specific Mortality After Acute Pulmonary Embolism: A Nationwide Cohort Study

急性肺栓塞后死因别死亡率的动态变化:一项全国性队列研究

Apixaban vs Placebo to Prevent Recurrences in Provoked Venous Thromboembolism With Enduring Risk Factors: One-Year Extension Results From the HI-PRO Trial

阿哌沙班与安慰剂预防伴持续危险因素的诱发性静脉血栓栓塞复发:HI-PRO试验一年延长期结果

A 4-Level Clinical Probability-Based Diagnostic Strategy for Suspected Pulmonary Embolism in Emergency Departments: A Cluster-Randomized Trial

急诊科疑似肺栓塞基于四级临床概率的诊断策略:一项整群随机试验

Amrecibart and Cenvacibart for the Prevention of Catheter-Related Thrombosis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial (ROXI-CATH)

Amrecibart与Cenvacibart预防导管相关血栓形成:一项2期随机双盲安慰剂对照试验(ROXI-CATH)

Featured Science in Acute Coronary Syndromes

北京时间:11月8日 02:30

Two-Week Helicobacter Pylori Eradication versus Six-Month Pantoprazole for Prevention of Gastrointestinal Bleeding After Percutaneous Coronary Intervention for Acute Coronary Syndrome: The VIHP Randomized Trial

两周幽门螺杆菌根除治疗与六个月泮托拉唑治疗预防急性冠状动脉综合征经皮冠状动脉介入治疗后胃肠道出血的比较:VIHP随机试验

Contemporary Cost-Effectiveness of Default Prasugrel versus Ticagrelor Policies in Acute Coronary Syndromes

急性冠状动脉综合征中默认普拉格雷策略与替格瑞洛策略的当代成本效益

Multimodality Cardiac Imaging Substudy of the DAPT-SHOCK-AMI Randomized Trial: Echocardiographic and Cardiac Magnetic Resonance Assessment of Cangrelor vs. Crushed Ticagrelor in Cardiogenic Shock Complicating Acute Myocardial Infarction

DAPT-SHOCK-AMI随机试验的多模态心脏影像亚研究:超声心动图与心脏磁共振评估坎格雷洛与碾碎替格瑞洛在急性心肌梗死并发心源性休克中的作用

One-Year Outcomes After Implementation of the 0/1-Hour Pathway: A Prespecified Secondary Analysis of a Randomized Controlled Trial

实施0/1小时路径后的一年结局:一项随机对照试验的预设次要分析

Periprocedural Myocardial Injury, Microaxial Flow Pump Use and Cardiovascular Death After Complex Percutaneous Coronary Intervention: Insights From a Pre-Specified Analysis of the CHIP-BCIS3 Trial

复杂经皮冠状动脉介入治疗后围手术期心肌损伤、微轴流泵使用与心血管死亡:CHIP-BCIS3试验预设分析的启示

Topline Results in Heart Rhythm Care

北京时间:11月8日 02:30

Clinical Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators: Late Follow-Up Results of the EU-CERT-ICD Controlled Multi Center Cohort Study

一级预防植入式心律转复除颤器的临床有效性:EU-CERT-ICD对照多中心队列研究的远期随访结果

Rethinking Atrial Fibrillation (AF) Burden: AF Density Further Stratifies Heart Failure Risk in a Nationwide Cohort of Patients With Cardiac Devices

重新思考心房颤动(AF)负荷:AF密度可在全国性心脏器械患者队列中进一步分层心力衰竭风险

Subclinical AF and Stroke: Is There a Safe AF Burden?

亚临床房颤与卒中:是否存在安全的房颤负荷?

First-in-Human Evaluation of Bay 3670549, a Selective GIRK4 Inhibitor for Pharmacological Cardioversion in Patients With Atrial Fibrillation

Bay 3670549(一种选择性GIRK4抑制剂)用于心房颤动患者药物复律的首次人体评估

Artificial Intelligence-Guided Electrocardiographic Risk Stratification With Targeted Ambulatory Monitoring for Early Detection of Atrial Fibrillation and Pre-Atrial Fibrillation Atrial Findings: The LATENT Randomized Clinical Trial

人工智能指导的心电图风险分层联合靶向动态监测用于早期检出心房颤动及心房颤动前心房异常:LATENT随机临床试验

Novel Lipid Lowering Therapies

北京时间:11月8日 04:25

SRSD216 a Once Yearly Novel Small Interfering RNA Therapeutic to Lipoprotein(a) Provides Time Averaged Annualized Reduction of 85% After a Single Dose - A Phase 1 Study

SRSD216:一种每年一次、靶向脂蛋白(a)的新型小干扰RNA治疗药物,单次给药后时间平均年化降幅达85%——一项1期研究

RN0361, a Novel Quaternary Gal-NAc siRNA, for the Treatment of Hypertriglyceridemia: A Phase 2a, Placebo-Controlled, Single Dose, Parallel Group Study

RN0361,一种新型四价GalNAc siRNA,用于治疗高甘油三酯血症:一项2a期、安慰剂对照、单次给药、平行组研究

First-in-Human Trial of a Dual Functional RNAi Molecule to Silence Expression of Both PCSK9 and APOC3 in Mixed Hyperlipidemia

一种双功能RNA干扰分子同时沉默混合型高脂血症中PCSK9和APOC3表达的首次人体试验

Anti-Inflammatory Efficacy and Safety of Oral NLRP3 Inhibitor Ruvonoflast: Results From the Phase 2 RESOLVE-1 Trial

口服NLRP3抑制剂Ruvonoflast的抗炎疗效与安全性:2期RESOLVE-1试验结果

Triglyceride Lowering and Acute Pancreatitis (AP) Risk Reduction With Plozasiran in Severe Hypertriglyceridemia (sHTG): A Pooled Analysis of SHASTA-3 and SHASTA-4

Plozasiran降低重度高甘油三酯血症(sHTG)患者甘油三酯并降低急性胰腺炎(AP)风险:SHASTA-3与SHASTA-4的汇总分析

Translating Evidence to Practice: Rigorous Evaluations of Human, Digital and Environmental Interventions

北京时间:11月8日 22:30

Lipoprotein(a), Aspirin and Cardiovascular Events in Older Adults

老年人中的脂蛋白(a)、阿司匹林与心血管事件

Home Blood Pressure Telemonitoring Linked With Community Health Workers to Improve Blood Pressure: The LINKED-BP Program Cluster-Randomized Controlled Trial

家庭血压远程监测联合社区卫生工作者改善血压:LINKED-BP项目整群随机对照试验

The Effect of a Community-Based Cardiovascular Health Intervention in Black Men on Life’s Essential 8 and Perceived Stress: Black Impact

社区心血管健康干预对黑人男性“生命八要素”及感知压力的影响:Black Impact研究

The Penn Medicine Healthy Heart Trial: Reducing Clinician Burden for ASCVD Risk Management

宾夕法尼亚大学医学健康心脏试验:减轻临床医生在动脉粥样硬化性心血管疾病(ASCVD)风险管理中的负担

Digital Outreach Modalities to Improve Statin Refill Adherence Across the Age Spectrum: Insights From the ADHERE-ASCVD Randomized Clinical Trial

改善各年龄段他汀类药物续配依从性的数字化触达方式:ADHERE-ASCVD随机临床试验的启示

Cleaner Air for Lower Cardiometabolic Risk: A Randomized, Double-Blind, Sham-Controlled Trial of Air Pollution Reduction

通过改善空气质量降低心脏代谢风险:一项随机、双盲、假干预对照的空气污染削减试验

Heart Failure Care for Novel Phenotypes

北京时间:11月8日 22:30

Impact of Intravenous Iron Repletion on Mechanisms of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: The IRONMET-HFpEF Trial Primary Results

静脉补铁对射血分数保留型心力衰竭运动不耐受机制的影响:IRONMET-HFpEF试验主要结果

Tirzepatide and Reverse Remodeling of the Left Atrium and Right Heart in Obesity-Related Heart Failure With Preserved Ejection Fraction

替尔泊肽与肥胖相关射血分数保留型心力衰竭中左心房和右心的逆向重构

Bax24 – Effect of Baxdrostat on 24-Hour Average Ambulatory Blood Pressure in Patients with Resistant Hypertension: The Bax24 Trial

Baxdrostat对耐药高血压患者24小时平均动态血压的影响:Bax24研究

Dapagliflozin for Renal Protection in Heart Transplant Recipients

达格列净对心脏移植受者的肾脏保护

Effects of Sotatercept on Cardiac Structure and Function: Analysis of the CADENCE Study

Sotatercept对心脏结构与功能的影响:CADENCE研究分析

ELPIS II: A Phase 2b Randomized Clinical Trial to Evaluate the Efficacy and Safety of Laromestrocel as Adjunct Therapy During Stage II Palliation for Hypoplastic Left Heart Syndrome

ELPIS II:一项2b期随机临床试验,评估Laromestrocel作为左心发育不良综合征Ⅱ期姑息治疗期间辅助治疗的疗效与安全性

Semaglutide Ameliorates the Seminal Hemodynamic Features of Obesity-Related HFpEF: A Placebo Controlled Randomized Clinical Trial

司美格鲁肽改善肥胖相关HFpEF的标志性血流动力学特征:一项安慰剂对照随机临床试验

Old Meds, New Meds and BP Goals: Optimizing Antihypertensive Therapy

北京时间:11月9日 04:30

Single-Pill Combination Strategy for Hypertension Control in Resource-Constrained Settings: A Cluster-Randomized Trial

资源受限环境下单片复方制剂策略用于高血压控制:一项整群随机试验

Transform-HTN: Long-Term Efficacy and Safety of Lorundrostat, a Novel Aldosterone Synthase Inhibitor, in Uncontrolled Hypertension

Transform-HTN:新型醛固酮合成酶抑制剂Lorundrostat在未控制高血压中的长期疗效与安全性

Angiotensinogen RNA Interference With LDR2402 for Hypertension

 LDR2402介导的血管紧张素原RNA干扰用于高血压

王继光 教授

Digital-Driven Solutions: Connecting the Patient and Provider for HF Transformation

北京时间:11月09日 04:30

Results of a Prospective, International, Multicenter, Pivotal Validation Study of Remote Voice Analysis for Monitoring Ambulatory Heart Failure Patients

远程语音分析监测门诊心力衰竭患者的前瞻性国际多中心关键验证研究结果

Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations for Heart Failure (BETTER CARE-HF) Multi-Center Trial: A Pragmatic Cluster Trial of an Ambulatory Alert Across Multiple Health Systems

构建电子工具以增强和强化心力衰竭心血管建议(BETTER CARE-HF)多中心试验:一项在多个卫生系统中评估门诊预警的实用性整群试验

A Multi-Center Randomized Controlled Trial of a Digital Health Intervention for Medication Optimization in Heart Failure

数字健康干预优化心力衰竭药物治疗的多中心随机对照试验

Randomized Evaluation of Education and Feedback and Referral Nudges to Increase Heart Failure Medication Optimization Among Primary Care Pharmacists in the Veterans Affairs Healthcare System (PHARM-HF 2 Trial)

在退伍军人事务医疗系统中随机评估教育与反馈及转诊助推措施以促进初级保健药师优化心力衰竭药物治疗(PHARM-HF 2试验)

Featured Science: Lp(a)

北京时间:11月09日 04:30

Optimization of Atherogenic Lipid Management With RN5681, a Bivalent SiRNA Targeting PCSK9 and Lp(a)

采用靶向PCSK9和Lp(a)的双价siRNA RN5681优化致动脉粥样硬化性脂质管理

FB7023, a Novel Dual-Targeting siRNA Against PCSK9 and Lpa, Simultaneously Reduces Both LDL-C and Lp(a), Exhibiting High-Value Treatment Potential for Management of ASCVD

 FB7023是一种靶向PCSK9和LPA的新型双靶向siRNA,可同时降低LDL-C和Lp(a),在ASCVD管理中展现出高价值治疗潜力

Prospective In Silico Prediction of the Lp(a) HORIZON Trial Using a Mechanistic Atherosclerotic Cardiovascular Disease Model

使用机制性动脉粥样硬化性心血管疾病模型对Lp(a) HORIZON试验进行前瞻性计算机模拟预测

Variability of Lipoprotein(a) Measurement Between Acute Myocardial Infarction at Admission, Discharge and Follow Up

急性心肌梗死入院、出院与随访期间脂蛋白(a)测量值的变异性

Silencing ATTR-CM: Lessons from Helios-B and CardioTransform

北京时间:11月08日 22:40

2-Year Results From the Open-Label Extension Period of the Phase 3 HELIOS-B Study of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Vutrisiran治疗转甲状腺素蛋白淀粉样变性伴心肌病患者的3期HELIOS-B研究开放标签延长期2年结果

The Effect of Vutrisiran on Exercise Capacity and Ventilatory Efficiency: Insights From the HELIOS-B CPET and Stress Echocardiography Subgroup Analysis

Vutrisiran对运动能力和通气效率的影响:HELIOS-B心肺运动试验与负荷超声心动图亚组分析的启示

Effects of Eplontersen on Cardiac Structure and Function in Patients With Transthyretin Amyloidosis With Cardiomyopathy - Insights From the CARDIO-TTRansform Trial

Eplontersen对转甲状腺素蛋白淀粉样变性伴心肌病患者心脏结构与功能的影响——CARDIO-TTRansform试验的启示

Myocardial Responses to Eplontersen in Transthyretin Amyloid Cardiomyopathy: The Cardio-TTRansform CMR Substudy

Eplontersen在转甲状腺素蛋白淀粉样心肌病中的心肌反应:Cardio-TTRansform CMR亚研究

Featured Science Potpourri

北京时间:11月09日 02:30

Health Economic Outcomes in the Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Randomized Trial

依洛尤单抗在无既往心肌梗死或卒中的高心血管风险患者中疗效随机试验的卫生经济学结局

Efficacy and Safety of Pelacarsen in Black/African American and Hispanic Participants With Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease: The Lp(a)FRONTIERS EXPANSION Study

Pelacarsen在脂蛋白(a)升高且已确诊动脉粥样硬化性心血管疾病的黑人/非裔美国人和西班牙裔参与者中的疗效与安全性:Lp(a)FRONTIERS EXPANSION研究

Test 2 Treat: A Hybrid Effectiveness-Implementation Trial to Improve LDL-C Testing and Management After Hospitalization for Atherosclerotic Cardiovascular Disease

Test 2 Treat:一项混合效果-实施试验,旨在改善动脉粥样硬化性心血管疾病住院后LDL-C检测与管理

Treating the Metabolic Syndrome With a Sodium-Glucose Cotransporter-2 Inhibitor: A Randomised Controlled Trial (TIME-SGLT2 Trial)

使用钠-葡萄糖协同转运蛋白2抑制剂治疗代谢综合征:一项随机对照试验(TIME-SGLT2试验)

ECG-AI-First Sequential Screening With NT-proBNP for Heart Failure Risk: The HeartShare/AMP-HF Pooled Cohort Study

心电图人工智能优先序贯筛查联合NT-proBNP评估心力衰竭风险:HeartShare/AMP-HF汇总队列研究

Results From Primary Analysis of the Coordinated versus Usual Nonpharmacologic Care for Postural Orthostatic Tachycardia Syndrome in Long COVID: A Pooled Analysis From the Recover-Autonomic Platform Trial

长新冠相关体位性心动过速综合征协调式与常规非药物护理比较的主要分析结果:RECOVER-Autonomic平台试验汇总分析

Treat, Test or Wait: New Randomized Evidence Across Valve Disease, Perioperative Care and Imaging

北京时间:11月09日 02:30

Transcatheter Aortic Valve Replacement or Clinical Surveillance for Moderate Aortic Stenosis: Primary Results From the Progress Randomized Trial

中度主动脉瓣狭窄的经导管主动脉瓣置换术或临床监测:PROGRESS随机试验主要结果

Early Percutaneous Mitral Commissurotomy versus Conventional Management for Asymptomatic Severe Mitral Stenosis: Final Outcomes of the MITIGATE Trial

无症状重度二尖瓣狭窄早期经皮二尖瓣交界分离术与常规管理的比较:MITIGATE试验最终结局

Routine Preoperative Echocardiography Before Intermediate-Risk Noncardiac Surgery: The PREOP-ECHO Randomized Clinical Trial

中危非心脏手术前常规术前超声心动图:PREOP-ECHO随机临床试验

Active Surveillance for Perioperative Myocardial Infarction/Injury With Robotic Process Automation: A Double-Blind Randomized Controlled Implementation Trial

基于机器人流程自动化的围手术期心肌梗死/损伤主动监测:一项双盲随机对照实施试验

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言

来源:梅斯医学·临床资讯 · news.medsci.cn